SCHEMBL23210895

SCHEMBL23210895

N#CC1(c2ccc(Br)cn2)CCN(C(=O)O)CC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.36
CA1 P00915 2/20 0.36
CA2 P00918 2/20 0.36
CA9 Q16790 2/20 0.36
ALDH1A1 P00352 3/20 0.36
KDM4E B2RXH2 1/20 0.36
SMO Q99835 1/20 0.36
CA7 P43166 1/20 0.36
CA14 Q9ULX7 1/20 0.36
TSHR P16473 3/20 0.35
POLB P06746 1/20 0.35
F11 P03951 2/20 0.35
AKR1C3 P42330 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
PRKCA P17252 1/20 0.34
PTPN2 P17706 1/20 0.34
HTR7 P34969 1/20 0.34
FFAR4 Q5NUL3 1/20 0.34
SPR P35270 1/20 0.34
HRH3 Q9Y5N1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23211114 0.92 CA12 (0.35) CA12CA1CA2CA9ALDH1A1
SCHEMBL23778451 0.83 HRH3 (0.40) HRH3
SCHEMBL15167113 0.82 JAK2 (0.44)
SCHEMBL30308796 0.82 JAK2 (0.44)
SCHEMBL5519697 0.81 FFAR4 (0.34) ALDH1A1KDM4ESMOFFAR4
SCHEMBL12489023 0.81 ALDH1A1 (0.40) CA12CA1CA2CA9ALDH1A1
SCHEMBL11963149 0.81 KDM4E (0.38) CA12CA1CA2CA9ALDH1A1
SCHEMBL2381444 0.79 CA12 (0.50) CA12CA1CA2CA9ALDH1A1
SCHEMBL761722 0.78 PRKCA (0.51) CA12CA1CA2CA9ALDH1A1
SCHEMBL877334 0.78 MAP3K12 (0.35) ALDH1A1KDM4ESMOFFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230338389-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2023-10-26 US disclosed
US-11607416-B2 Bicyclic heterocycles as FGFR inhibitors INCYTE CORPORATION (US) 2023-03-21 US disclosed
EP-4045151-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS Incyte Corporation (US) 2022-08-24 EP disclosed
WO-2021076602-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION (US) 2021-04-22 WO disclosed
US-20210106588-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2021-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210106588-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS FGFR1, FGFR3, FGFR2 CA12 4316/4885CA1 4535/4885CA2 3078/4885
US-11607416-B2 Bicyclic heterocycles as FGFR inhibitors FGFR1, FGFR3, FGFR2 CA12 4316/4885CA1 4535/4885CA2 3078/4885
US-20230338389-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS FGFR1, FGFR3, FGFR2 CA12 4316/4885CA1 4535/4885CA2 3078/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.